Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) CFO Michael F. Maclean sold 104,245 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $35.72, for a total transaction of $3,723,631.40. Following the completion of the sale, the chief financial officer now directly owns 44,093 shares in the company, valued at $1,575,001.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Avidity Biosciences Trading Down 0.8 %
Avidity Biosciences stock traded down $0.32 during mid-day trading on Friday, reaching $39.64. The company’s stock had a trading volume of 4,730,468 shares, compared to its average volume of 1,245,588. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of -13.44 and a beta of 0.81. The business has a 50 day moving average price of $27.05 and a 200-day moving average price of $18.72. Avidity Biosciences, Inc. has a twelve month low of $4.82 and a twelve month high of $42.00.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.02. Avidity Biosciences had a negative net margin of 2,103.78% and a negative return on equity of 37.98%. The company had revenue of $3.54 million during the quarter, compared to the consensus estimate of $7.09 million. On average, equities analysts expect that Avidity Biosciences, Inc. will post -3.1 EPS for the current fiscal year.
Hedge Funds Weigh In On Avidity Biosciences
Wall Street Analyst Weigh In
Several research firms have issued reports on RNA. Chardan Capital raised their price target on shares of Avidity Biosciences from $33.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday. Evercore ISI raised their price target on shares of Avidity Biosciences from $40.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $35.00 price objective on shares of Avidity Biosciences in a research note on Monday. Cantor Fitzgerald started coverage on shares of Avidity Biosciences in a research note on Thursday, March 14th. They set an “overweight” rating and a $60.00 price objective on the stock. Finally, Bank of America lifted their price objective on shares of Avidity Biosciences from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $44.29.
Check Out Our Latest Stock Analysis on Avidity Biosciences
About Avidity Biosciences
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Read More
- Five stocks we like better than Avidity Biosciences
- Top Stocks Investing in 5G Technology
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
- What Are Dividend Champions? How to Invest in the Champions
- Adobe Stock: It’s Not Too Late To Buy The Dip
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.